HEALTH CATALYST INCHCAT
ASignal's systematic analysis rates HCAT as Bearish.
Reflects the latest available analysis · analyzed Oct 23, 2026
The case on HCAT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Gross margin of 51.16% indicates strong pricing power
- Current ratio of 2.70x suggests solid short-term liquidity
- Price near lower Bollinger Band (1.7028) may indicate potential reversal support
- Negative free cash flow (-$48.65M) raises sustainability concerns
- High debt-to-equity ratio (1.69x) increases financial risk
- Negative ROE (-118.12%) and negative net margin (-90.61%) reflect severe profitability issues
- Declining revenue growth (YoY: -12.7%) indicates shrinking business scale
- MACD below signal line with negative histogram suggests ongoing downtrend
See the full verdict on HCAT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes HCAT
Most investors never get a second opinion, let alone several. ASignal runs HCAT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.